Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Open accessThe DOI matches its Crossref record; 773 of the 831 references it cites were found in a registry or an index; 177 of the 559 sources its claims cite were checked for support.
Abstract
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting cortisol biosynthesis. Reduced activity of an enzyme required for cortisol production leads to chronic overstimulation of the adrenal cortex and accumulation of precursors proximal to the blocked enzymatic step. The most common form of CAH is caused by steroid 21-hydroxylase deficiency due to mutations in CYP21A2. Since the last publication summarizing CAH in Endocrine Reviews in 2000, there have been numerous new developments. These include more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods. Clinical trials of alternative medications and modes of delivery have been recently completed or are under way. Genetic and cell-based treatments are being explored. A large body of data concerning long-term outcomes in patients affected by CAH, including psychosexual well-being, has been enhanced by the establishment of disease registries. This review provides the reader with current insights in CAH with special attention to these new developments.
Overview
CoChat Summary
TL;DR
This review summarizes current understanding of congenital adrenal hyperplasia (CAH), predominantly 21-hydroxylase deficiency (21OHD), covering steroidogenesis, genetics, diagnosis, management, and long-term outcomes. It emphasizes a phenotypic continuum, newer biomarkers and therapies, and persistent evidence gaps in treatment and surgical care.
Key findings
- 21OHD accounts for approximately 90–99% of CAH; classic CAH incidence is about 1 in 14,000 to 18,000 by newborn screening, while nonclassic (NC) CAH is estimated at ~1 in 200 in the Caucasian population.
- Genotype correlates with the less severely impaired CYP21A2 allele: 96% of individuals with two Group 0 alleles have salt-wasting CAH, whereas 97% of those with at least one Group C allele have NC CAH; residual enzyme activity is ~1–5% in simple virilizing and ~20–50% in NC CAH.
- Long-term sequelae include testicular adrenal rest tumors (TARTs) in males (reported prevalence 14–86%, average 25% in adolescents and 46% in men), adrenal masses in ~20–30% of adults, and increased mortality; adrenal crises caused 42% of deaths in a Swedish cohort, with mean age at death 54.8 years versus 72.8 years in controls.
- Newer concepts include 11-oxo-androgens such as 11-ketotestosterone as biomarkers, the backdoor pathway to dihydrotestosterone, and novel therapies (CRHR1 antagonists, abiraterone, modified-release hydrocortisone, gene/cell-based approaches), though many lack peer-reviewed long-term outcomes.
Methods
- Narrative, multi-authored review resulting from a planned European CAH Symposium postponed due to the COVID-19 pandemic; it covers pathophysiology, diagnostics, management, long-term sequelae, developing-country challenges, and future directions.
- Evidence base is a synthesis of published literature, clinical guidelines (including the 2018 Endocrine Society guideline), registries, observational studies, meta-analyses, and clinical trials; no primary patient cohort or systematic search is described.
- Main analysis is narrative synthesis, with tables and figures summarizing incidence, allele frequencies, treatment dosing, monitoring, and prenatal dexamethasone outcomes.
Limitations
- Stated: there are no large-scale prospective randomized trials for any therapies discussed; evidence is generally low or moderate quality and rests partly on expert opinion, values, and preferences.
- Stated: no evidence-based guidelines for surgical management exist, and there are no studies comparing different feminizing surgery techniques or early versus late surgery; genotype-phenotype correlations are strong but not absolute, and many neuroimaging studies are hindered by small sample size.
- Evident: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or quantitative synthesis; conclusions depend on the cited literature and expert consensus.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
86 Valid · 78 Not valid · 186 Not checked · 76 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Supraphysiological dosages of glucocorticoids similar to those used to treat classic CAH patients may be necessary to suppress adrenal androgen production (426).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Growth
What the sources say
- Disputedcites [426] Livadas, 2019, Management of the female with non-classical congenital adrenal hyperplasia (NCCAH): a patient-oriented approach, Front Endocrinol (Lausanne). sourceExperimental — accuracy not yet measured
In “NCCAH Management From the First Manifestation to the Adult Life” (page unavailable), the paper says glucocorticoids are generally given at replacement, not pharmacological, doses to decrease adrenal androgen production. Its “Management During Childhood” section adds that very high doses are needed to suppress 17-OHP and progesterone, not that supraphysiological doses are necessary to suppress adrenal androgens. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Females do outnumber males in some(12,240,241) although not all (242) retrospective studies in which CAH was clinically diagnosed without neonatal screening.”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Table 7
What the sources say
- Not checked — no full text of the sourcecites [12] Dumic, 2009, Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006, Horm Res. source
- Not checked — no full text of the sourcecites [240] Hird, 2014, No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening, Arch Dis Child. source
- Disputedcites [241] Riedl, 2019, Genotype/phenotype correlations in 538 congenital adrenal hyperplasia patients from Germany and Austria: discordances in milder genotypes and in screened versus prescreening patients, Endocr Connect. sourceExperimental — accuracy not yet measured
Citation (242) is attached to “not all,” offering this study as an example of a retrospectively studied, clinically diagnosed prescreening group without a female majority. The Results (Eligible patients; page unavailable) say the opposite: females made up 64% of the prescreening group. The approximately equal sex distribution was in the screened group, which does not fit that clause. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A single-dose, fixed-sequence study of 8 women given 300 or 600 mg of the CRHR1 antagonist NBI77860 at 2200 (10 PM) showed significant reductions in ACTH and 17OHP over the ensuing 16 hours relative to a control period during which glucocorticoid treatment was withheld (498).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > D. New medical strategies (Figure 5)
What the sources say
- Disputedcites [498] Sanders, 2018, Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies, Vet Res Commun. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plainstates a causen = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Excessive nighttime glucocorticoid administration has potential adverse metabolic consequences (371,382).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Table 7
What the sources say
- Not checked — no full text of the sourcecites [371] Han, 2013, Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia, Clin Endocrinol (Oxf). source
- Partly supportedcites [382] Whitaker, 2014, An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure, Clin Endocrinol (Oxf). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says cortisol is normally low around midnight and that loss of its rhythm is associated with insulin resistance. It also suggests physiological replacement may help metabolic homeostasis. These passages support a potential metabolic concern, but the paper does not specifically state that excessive nighttime glucocorticoid administration has adverse metabolic consequences. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Low expression of CYP21A2 during the second trimester partially explains the high incidence of false-positives in newborn screens for CAH in premature infants (see section IV.A)(159).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Pattern of CYP21A2 expression
What the sources say
- Could not verifycites [159] Zhou, 1997, Steroid 21-hydroxylase expression and activity in human lymphocytes, Mol Cell Endocrinol. sourceExperimental — accuracy not yet measured
Section 3.1 reports CYP21 expression in cultured lymphoid cells, including cells from CAH patients, but does not examine expression during the second trimester. Searches for premature infants, newborn screening, and false positives found no passage addressing the proposed explanation. (LLM, conf=0.76)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
207 more claims · 72 with their cited sources checked
Create a free account to see all 426 claims and to verify the 50 references still open.
- It may state two separate claims as one. 172
- Probably not a substantial claim. 64
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several reports in European, Mediterranean, Middle Eastern, and Chinese populations confirmed a high frequency of the pathogenic IVS2-13A/C > G and found it to comprise 20 to 25% of the CYP21A2 mutant alleles and to translate to the most severe SW forms of the disease when inherited in homozygosity [1, 4, 27, 39–43].”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When combined with complementary methods such MLPA for copy number analysis, it provides nearly complete diagnostic coverage, identifying up to 98-99% of classical pathogenic alleles in most populations (1, 16, 76).”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [76]
In the citing paper
“Although CAH is rare, the most common form is caused by steroid 21-hydroxylase deficiency (21-OHD) and is an autosomal-recessive disorder of adrenal steroidogenesis that results from CYP21A2 mutations.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [1]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Sodium chloride supplements 1-2 g (17-24 mEq/day) in infancy”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Graphical Abstract
Reported 24 · recomputed 34
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“A recent meta-analysis of 48 CAH cases, 34 (71%) described symptomatic improvement after bilateral adrenalectomy but with 34 cases (10%) reporting short-term and 13 cases (27%) long-term adverse outcomes”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > D. New medical strategies (Figure 5)
Reported 10 · recomputed 70.833333
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Presence of fetal DNA in maternal plasma and serum
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02174-0 · Cited by 3,129
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationConsensus Statement on Management of Intersex Disorders
Lee, P. A., Houk, C. P., Ahmed, S. F., Hughes, I. A., & in collaboration with the participants in the International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology (2006) · Pediatrics · doi:10.1542/peds.2006-0738 · Cited by 2,324
Self-citationBornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Self-citationAromatase Cytochrome P450, The Enzyme Responsible for Estrogen Biosynthesis*
SIMPSON, E. R., MAHENDROO, M. S., MEANS, G. D., KILGORE, M. W., HINSHELWOOD, M. M., GRAHAM-LORENCE, S., AMARNEH, B., ITO, Y., FISHER, C. R., MICHAEL, M. D., et al. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-342 · Cited by 1,537
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Self-citation
Research works printed but not linked: 2
- McCann-Crosby, 2014, Non classic CAH; targets of treatment and transition, Pediatr Endocr Rev., 12, 224
- Auchus, 2012, Abiraterone acetate added to physiologic hydrocortisone dosing safely controls androgen excess in adult women with classical 21-hydroxylase deficiency, Endocr Rev., 33, SUN-LB2
Cited by
Items 501–554 of 554
Ghareeb, B. M., Shakeeb, F. N., Busehail, M. Y., & Alarrayedh, M. (2026) · Cureus · doi:10.7759/cureus.108805 · Cited by 1
Kim, H., Lin, V. H., Newfield, R. S., Dauber, A., Luo, M., Cicero, S., Li, M., Zhao, C., & Cheng, H. K.-H. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag112
“In practice, when using GCs to reduce ACTH-driven adrenal androgen production without adjunctive therapy, supraphy-siologic GC doses are typically required [2, 4, 6, 9].”
InfluentialUrologic Emergencies in Children: Special Considerations
Chuang, K., & Khoury, A. (2026) · Springer eBooks · doi:10.1007/978-3-031-52619-0_10
Congenital adrenal hyperplasia
Vorontsova, M. V., Кокорина, Т. С., Nuralieva, N. F., Yukina, M. Y., Troshina, E., Mel'nichenko, G. A., & Mokrysheva, N. G. (2026) · Problems of Endocrinology · doi:10.14341/probl13763
Flokas, M. E., Kulkarni, S., Lee, P., Li, Y., Sukin, C., Kollender, S., & Merke, D. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1810137
Self-citationApproach to the patient: investigation of postmenopausal androgen excess
Madden-Doyle, L., Bowers, K., Sherlock, M., & O’Reilly, M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag221 · Cited by 1
Weil, L., Hoebeke, P., Kalfa, N., et al. (2026) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2026.106061
21‐Hydroxylase Deficient Congenital Adrenal Hyperplasia Due to Maternal Uniparental Isodisomy
Kluge, M. L., Schema, L., Schroepfer, K., Thoreson, E. K., Sarafoglou, K., Rowsey, R. A., Marcou, C. A., Moyer, A. M., & Schultz, M. J. (2026) · Case Reports in Endocrinology · doi:10.1155/crie/3596318
Growth patterns in patients with congenital adrenal hyperplasia analyzed by the QEPS growth model
Navardauskaitė, R., Niklasson, A., Nierop, A. F. M., Pivodic, A., Verkauskienė, R., & Holmgren, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1736405
“Thus, impaired adult height may result not only from advanced skeletal maturation due to androgen excess but also from overtreatment-related growth inhibition, emphasizing the narrow therapeutic window in CAH management (45, 46).”
Integrated mapping resolves pathogenicity of 11 CYP21A2 variants in congenital adrenal hyperplasia
Xu, Y., Matveeva, A., Jørgensen, F. S., & Pandey, A. V. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag127 · Cited by 2
“A deficiency in 21-hydroxylase activity disrupts these pathways, leading to a cascade of pathophysiological consequences [3-5].”
Zykova, S. N., Plaksienko, A., Solevåg, A. L., Brigtsen, A. K., Michelsen, T. M., Sørbye, I. K., Bentsen, M. H. L., Bakke, L. H., Elboth, J. E., Berg, J. P., et al. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1808446 · Cited by 1
Editorial: Advanced genomic techniques for congenital adrenal hyperplasia
Çetinkaya, S., & Falhammar, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1882809
Self-citationTizianel, I., Ceccato, F., & Barbot, M. (2026) · Frontiers in Adolescent Medicine · doi:10.3389/fradm.2026.1827315
Medical and social challenges awaiting adolescents with congenital adrenal hyperplasia
Nixon, M., & Davies, J. H. (2026) · Frontiers in Adolescent Medicine · doi:10.3389/fradm.2026.1870467
“These precursors can be converted to testosterone, 11-keto-testosterone, 11-keto-DHT or dihydrotestoserone (DHT), the latter via the backdoor pathway (5, 13).”
InfluentialДорош, О., Левінтанус, В., Feskova, A., Feskov, O. M., Feskova, I., Konoplia, L., & Герасименко, Л. В. (2026) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2026.2.09
Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia
Goai, W. H., & Torpy, D. J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2695099
Liu, Y., Zhang, C., Lu, R. Q., Li, R., Wang, Y., & Wang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1864787
Organoid-like Functional Adrenal Gland Cortex Derived From Human Pluripotent Stem CellsPreprint
MCALPINE, J. N., James, C., Dalal, B., Thomas, K., Knight, T., & Zeltner, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.30.735632
Psychosocial retrospective follow-up of young adults with congenital adrenal hyperplasia
Ekbom, K., Lajić, S., Falhammar, H., & Nordenström, A. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag119
Self-citationThe gut microbiome as a therapeutic potential for inborn errors of metabolism disorders
Parihar, S., Kumar, L., Dube, S., & Mohanty, S. S. (2026) · Discover Medicine · doi:10.1007/s44337-026-00640-6
Wang, J., He, S., Pang, X., & Zhang, W. (2026) · BMC Anesthesiology · doi:10.1186/s12871-026-04071-9
“In previously published literature, CAH has mainly been discussed from the perspective of endocrine diagnosis, chronic hormone replacement, and prevention or treatment of adrenal insufficiency [1–3, 6, 10, 11].”
Lankes, E., Wiebelt, L., Helge, K., Schnabel, D., Kühnen, P., Blankenstein, O., & Neumann, U. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854737
Be alert to hypertension caused by 17α-hydroxylase deficiency: two case reports in young patients
Zhang, Y., Lu, Y., Xie, X., & Gu, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261461859
“14,15 Dexamethasone, on the other hand, provides stronger ACTH suppression and is easier to administer once daily, though metabolic and skeletal side effects remain a concern.”
Anaforoğlu, İ., & Ertörer, M. E. (2026) · HORMONES · doi:10.1007/s42000-026-00808-w · Cited by 1
Gürbüz, E., Kocaay, P., Çetin, S. K., Tepe, D., Genç, C. A., Demirtaş, Ş., Boyraz, M., Keçeli, A. M., & Gürbüz, F. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02984-3
Kocaay, P., Gürbüz, E., Çetin, S. K., Kırgıl, B. N., Tepe, D., Genç, C. A., Tolunay, O., & Gürbüz, F. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07261-2
Karagüzel, G., Erkul, E., Aliyazıcıoğlu, Y., Sönmez, B., & Beyhun, N. E. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07245-2
Bilateral giant myelolipomas in a female patient with untreated 21-hydroxylase deficiency
Welp, A.-C., Auer, M. K., Tschaidse, L., Zimmermann, P., Braunschweig, T., & Reisch, N. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag176
“Loss of negative feedback in 21-OHD leads to chronic ACTH hypersecretion, driving adrenal hyperplasia and adrenal androgen excess [3, 4].”
Self-citationTao, Y., & Ji, R. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112876
Reproductive and fertility challenges in adolescents with congenital adrenal hyperplasia
Tschaidse, L., Auer, M. K., Nowotny, H. F., & Reisch, N. (2026) · Frontiers in Adolescent Medicine · doi:10.3389/fradm.2026.1878713
“Depending on the degree of virilization, surgery may be necessary to reduce urogenital complications such as infections associated with a persistent urogenital sinus and to create anatomical conditions that may permit future sexual intercourse and spontaneous conception (35).”
Self-citationCrinecerfont: emerging role in the management of congenital adrenal hyperplasia
Fedorova, O., & Falhammar, H. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2713482
Self-citationHippocampal volume and white matter impairments in patients with congenital adrenal hyperplasia
Savoia, A., Kancsar, D., Nordenström, A., Westeinde, A. V., & Lajić, S. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag312
Self-citationAntysheva, Z., Bogdanov, V. P., Rutkovskaya, E. A., Stepanova, A., Esibov, A. A., Krupinova, J., Shchekina, V. S., Avsievich, E., Tatyana, F., Bazarova, E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156938
“This gene has a highly homologous pseudogene, CYP21A1P , and is situated in the highly repetitive and complex RCCX locus [9].”
InfluentialGenetic characteristics and clinical features of pediatric congenital adrenal hyperplasia in Korea
Kim, I., Cho, M. H., Lee, Y. A., Lee, Y. J., Cheon, C. K., Suh, J., Moon, J.-E., Kim, C. J., Lim, H. H., Ahn, M. B., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04718-0
Giri, D., Alderson, J., Bashir, M., Shalaby, M. S., Williams, C., & Park, J. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0106
“However, the distinct biochemical pro fi le of elevated DOC and 11-deoxycortisol is important for accurate diagnosis and management and should be con fi rmed with genetic testing [1, 3, 11].”
Çelik, N. B., Şenkalfa, B., Vurallı, D., Özön, Z. A., & Gonc, E. N. (2026) · Kırıkkale Üniversitesi Tıp Fakültesi Dergisi · doi:10.24938/kutfd.1829514
de Sousa, A. G. P., Bezerra, A. D. A., & Chaves, C. E. D. P. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag224
“Testicular adrenal rest tumors (TARTs) are a well-recognized CAH complication, composed of vestigial adrenal cells within the testes [1, 2].”
Guo, C., Zhang, X., Lü, L., Cao, Y., Zhang, W., Wu, X., Tong, A., Chen, S., Wang, X., Mao, J., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03019-7 · Cited by 1
Lee, H. J., Chiu, C.-F., Huang, Y.-C., Huang, C.-C., & Lo, F. (2026) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2026.05.006
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Self-citationLarasati, I. A., Ulvyana, V., Hardian, H., Utari, A., & Winarni, T. I. (2026) · Belitung Nursing Journal · doi:10.33546/bnj.4312
Self-citationZhang, W., Zeng, J., Li, Y., Xie, C., Sun, Z., Lyu, G., Yan, T., & Huang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1896956
Tenaya, W. J., Nugraha, M., Susanto, J. V., Liu, A. F., Wijaya, S. R., & Pramono, L. A. (2026) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.041.02.6237
Decoding the CRH system from clinical failures to therapeutic translation
Silva, M. P. D., Williams, S., Mastorakos, G., Lehnert, H., Chrousos, G. P., & Grammatopoulos, D. K. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.08.002
Luo, Y., Liu, L., Zhou, X., Jiao, Y., Tang, M., Feng, W., Chunlan, D., Liu, X., Yang, L., Liu, F., et al. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05673-0
Tizianel, I., Bovo, G., Mazzeo, P., Ceccato, F., & Barbot, M. (2026) · Frontiers in Adolescent Medicine · doi:10.3389/fradm.2026.1919128
“Exposure to elevated ACTH levels, and possibly angiotensin II, beginning in utero and continuing postnatally, may stimulate the proliferation of these adrenal rest cells, which express ACTH and angiotensin II receptors (3).”
Sari, J. I., Utari, A., & Ediati, A. (2026) · Journal of Genetic Counseling · doi:10.1002/jgc4.70293
Self-citationEl-Taravi, Y., Ebanoidze, L. G., Vorotnikova, S. Y., Vorontsova, M. V., Игоревна, С. А., & Молашенко, Н. В. (2026) · Russian Journal of Human Reproduction · doi:10.17116/repro202632041124
Szklarz, M., Wołos-Kłosowicz, K., Szulc, J., Górny, J. M., & Matuszewski, W. (2026) · Middle East Fertility Society Journal · doi:10.1186/s43043-026-00364-8
“However, such treatment should be individualized, preferably short-term, and carefully balanced against the increased risk of metabolic adverse effects associated with supraphysiological glucocorticoid exposure [36, 79].”
Liu, Y., Cai, S., Zhang, T., Sun, S., Kong, X., Zhou, J., Chen, B., & Li, Z. (2026) · Endocrine · doi:10.1007/s12020-026-04767-5
Tuli, G., Munarin, J., Pavanello, E., & SANCTIS, L. D. (2026) · Endocrine · doi:10.1007/s12020-026-04759-5
Ünsal, İ. Ö., Fedai, N. K., Hepşen, S., Uçan, B., Özbek, M., & Çakal, E. (2026) · Endocrine · doi:10.1007/s12020-026-04801-6
Gawlik, Z., Gawlik, J., Tyrawa, K., Starzyk, J., & Januś, D. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07454-9
Papadakis, J. L., Whitehead, J., Poquiz, J. L., Johnson, E. K., Finlayson, C. A., & Chen, D. (2026) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-026-10174-9
Metadata
- Authors
- Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., Krone, N., Merke, D. P., Miller, W. L., Nordenström, A., Reisch, N., Sandberg, D. E., Stikkelbroeck, N. M. M. L., Touraine, P., Utari, A., Wudy, S. A., & White, P. C.
- Affiliations
- Department of Pediatric Endocrinology, Radboud University Medical Centre, Amalia Childrens Hospital, Nijmegen, The Netherlands
- Northwell Health (US)
- University of Glasgow (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of Michigan (US)
- Karolinska University Hospital (SE)
- University of Bern (CH)
- Queen Mary University of London (GB)
- Technische Universität Dresden (DE)
- Radboud University Medical Center (NL)
- University Hospital Carl Gustav Carus (DE)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of California, San Francisco (US)
- LMU Klinikum (DE)
- Sorbonne Université (FR)
- Diponegoro University (ID)
- Justus-Liebig-Universität Gießen (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- White, Perrin C
- ORCID
- Claahsen - van der Grinten, Hedi L
- Speiser, Phyllis W
- Ahmed, S Faisal
- Arlt, Wiebke
- Auchus, Richard J
- Falhammar, Henrik
- Flück, Christa E
- Guasti, Leonardo
- Huebner, Angela
- Krone, Nils
- Merke, Deborah P
- Miller, Walter L
- Nordenström, Anna
- Reisch, Nicole
- Sandberg, David E
- Touraine, Philippe
- Utari, Agustini
- Wudy, Stefan A
- White, Perrin C
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-05-07
- Volume
- 43
- Issue
- 1
- Pages
- 91-159
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W4229036110
- Semantic Scholar
- 1867a4639fab9f23f14102ccc6107c07963e64dc
- Cited by
- 556
- References
- 831
- Citations by year
- 2026: 102 · 2025: 125 · 2024: 149 · 2023: 97 · 2022: 68 · 2021: 14
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institutes of Health (U01-HD083493)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, CYP21A2 mutations, cortisol production, steroidogenic pathway, newborn screening, steroid profiling, genotyping, cell therapy, gene therapy, long-term outcomes, disease registries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.